Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,320 across all filing types
Latest filing 2025-12-08 Regulatory Filings
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison
Regulatory Filings Classification · 95% confidence The document is a press release issued by Photocure ASA announcing the presentation of a health economics abstract from the BRAVO study at the Society of Urologic Oncology 2025 Annual Meeting. It summarizes the study's findings regarding cost neutrality in bladder cancer treatment. As it is a corporate announcement regarding research findings and does not fit into specific financial reporting categories like 10-K or IR, and is not a formal regulatory filing, it falls under the general category of regulatory announcements/press releases.
2025-12-08 English
New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management - Attachment: Release.pdf
Regulatory Filings Classification · 100% confidence The document is a press release issued by Photocure ASA announcing the publication of a clinical study in the Journal of Medical Economics. It summarizes the study's findings regarding the economic impact of their product, BLC, in European markets. As it is a corporate announcement regarding a report publication rather than the report itself, and it does not fit into specific categories like earnings releases or financial reports, it is classified as a general regulatory/corporate announcement.
2025-11-19 English
New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management
Regulatory Filings Classification · 100% confidence The document is a press release issued by Photocure ASA announcing the publication of a clinical study in the Journal of Medical Economics. It summarizes the study's findings regarding the economic impact of their product, BLC, in European markets. As it is a corporate announcement regarding a publication rather than a formal financial report, regulatory filing, or investor presentation, it falls under the category of general regulatory announcements/press releases.
2025-11-19 English
Photocure ASA: Notification of primary insider transaction - Attachment: 20251030_Photocure_ASA_Primary_insider_notification_Neal_Shore_MAR_art_19_14238706_1.pdf
Director's Dealing Classification · 100% confidence The document is a formal notification of a transaction by a person discharging managerial responsibilities (PDMR), specifically Neal Shore, a member of the board of directors of Photocure ASA. It follows the standard Market Abuse Regulation (MAR) Article 19 disclosure format, detailing the purchase of shares. This falls directly under the definition of Director's Dealing (DIRS).
2025-10-31 English
Photocure ASA: Notification of primary insider transaction - Attachment: Release.pdf
Director's Dealing Classification · 100% confidence The document is a notification of a share transaction by a board member (Neal Shore) of Photocure ASA. It explicitly mentions 'Notification of primary insider transaction' and cites the Market Abuse Regulation Article 19, which is the standard regulatory requirement for reporting director/insider dealings. This fits the definition of 'Director's Dealing' (DIRS).
2025-10-31 English
Photocure ASA: Notification of primary insider transaction
Director's Dealing Classification · 100% confidence The document is a short notification regarding a share acquisition by a board member (Neal Shore). It explicitly mentions 'Notification of primary insider transaction' and cites the market abuse regulation article 19, which is the standard regulatory requirement for reporting director dealings. Since it reports a personal share transaction by a company director, it falls under the 'Director's Dealing' category.
2025-10-31 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.